

Antisense-targeted immuno-EM localization of the pre-mRNA path in the spliceosomal C complex

Elmar Wolf¹, Berthold Kastner*, Reinhard Lührmann*

Department of Cellular Biochemistry
Max Planck Institute for Biophysical Chemistry
37077 Göttingen
Germany




¹present address: Theodor-Boveri-Institut, Biocenter, Universität Würzburg, Am Hubland, 97074
Würzburg, Germany

Supplementary materials

Legend Figure S1: Accessibility of pre-mRNA regions within the C complex to digestion by RNase H upon addition of complementary oligodeoxyribonucleotides to HeLa nuclear extract. C complexes assembled on ³²P-labeled PM5 pre-mRNA were incubated together with DNA oligonucleotides complementary to selected pre-mRNA regions. Pre-mRNA bound by DNA is then cleaved by the RNase H present in the extract. The cleavage products were separated by gel electrophoresis and visualized by autoradiography of the gels. An intact C complex is indicated by the presence of the splicing intermediates (cleaved 5' exon and the intron lariat), and their degradation implies accessibility of the sequence in the C complex. All of the cleavage products showed the expected gel-electrophoretic migration behavior after RNase H digestion.

(A) The oligonucleotide number shown defines the sequence of the oligonucleotide used. The complementary binding sites of these oligonucleotides on the pre-mRNA sequence are shown in. Oligonucleotides that led to cleavage of the target region of the pre-mRNA in complex C are shown in red. The oligonucleotides shown in green did not lead to cleavage. (B) Initial RNase H screen with DNA oligonucleotides complementary to various regions of the pre-mRNA. At the right of each gel the positions of the unspliced pre-mRNA and splicing intermediates are shown; length standards are also shown, with the respective numbers of nucleotides. (C–H) High-resolution RNase H screen with DNA oligonucleotides complementary to the regions where accessible pre-mRNA becomes inaccessible. The borders between accessible and inaccessible regions were mapped with oligonucleotides spaced 2 nucleotides apart. (E) RNase H screen of the 5' splice site and test of the oligonucleotide lengths and oligonucleotide modifications. The accessibility for cleavage by RNase H at the 5' splice site and the influence of oligonucleotide length (right-hand autoradiogram, left half) was checked. In addition to the 12 nucleotide-long oligonucleotides used in the screen (e.g., oligonucleotide 113), the use of shorter oligonucleotides also led to cleavage, but no cleavage was observed with an oligonucleotide length of 8 nucleotides (oligonucleotide 117). We also investigated whether terminal biotin-labeling affected binding of the oligonucleotide and therefore the activity of RNase H (right-hand autoradiogram, right-hand side). Efficient binding and digestion by RNase H was not prevented by biotinylation either at the 3' end (oligonucleotide Bio-3') or at the 5' ends (Bio-5'); compare with the non-biotinylated oligonucleotide 121.

Figure S2



Legend Figure S2: Confirmation of the specific binding of the anti-biotin antibody to oligonucleotide-labeled C complexes. (A) Detection by ELISA of anti-biotin antibodies in the purification of labeled and unlabeled C complexes. Anti-biotin antibodies were added to oligonucleotide-labeled C complexes (biotinylated oligonucleotide ‘label intron anchoring site’; see Fig. 2 of the main text) and to unlabeled C complexes. Photographs of the original ELISA plates (right) and their quantitative photometric assessment (left) are shown. After the addition of antibodies a strong ELISA signal was seen (yellow coloration, see “I” and “input”). After incubation with the antibody, both C-complex samples were affinity-purified on an amylose matrix. While the C complexes bound to the matrix, most of the anti-biotin antibodies were found in the flow-through, and in the final washing step no antibodies were detected. When the oligonucleotide-labeled C complexes were eluted, they were found to contain anti-biotin antibodies. In contrast, hardly any antibody was co-eluted together with the unlabeled C-complex. This shows, that most of the anti-biotin antibodies bind specifically the biotinylated oligonucleotide with which the c complexes are labeled. (B,C) The (anti-biotin–C complex) immunocomplexes remain intact during the subsequent GraFix centrifugation. To investigate the association of the anti-biotin antibody with the C complex during the GraFix gradient centrifugation (which preceded the EM preparation), anti-Biotin antibody-labeled and affinity-purified C complexes were, then subjected to GraFix centrifugation and finally fractionated. In the fractions, the quantities of C complex were measured by scintillation counting (blue curve) and the quantities of antibodies were measured by ELISA (red curve). The purified oligonucleotide-labeled and anti-biotin-treated C complexes (B) sedimented around fraction 17, where the anti-biotin antibodies also sedimented. Unlabeled C complexes (C) sedimented in comparable fractions (peak at 16; blue curve). However, unlike the oligonucleotide-labeled complexes, no antibody was detected in these fractions. The small quantity of co-eluted anti-biotin antibodies migrated in the light fractions of the gradient (3–8) and were not associated with complex C.